EP2384138A2 - Verfahren und vorrichtung zum ermitteln und/oder überwachen eines körperlichen zustandes basierend auf einer amplitude eines drucksignals, insbesondere des herzdrucksignals während einer blutbehandlung - Google Patents
Verfahren und vorrichtung zum ermitteln und/oder überwachen eines körperlichen zustandes basierend auf einer amplitude eines drucksignals, insbesondere des herzdrucksignals während einer blutbehandlungInfo
- Publication number
- EP2384138A2 EP2384138A2 EP09765044A EP09765044A EP2384138A2 EP 2384138 A2 EP2384138 A2 EP 2384138A2 EP 09765044 A EP09765044 A EP 09765044A EP 09765044 A EP09765044 A EP 09765044A EP 2384138 A2 EP2384138 A2 EP 2384138A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- amplitude
- pressure signal
- patient
- signal
- physical condition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
- A61B5/021—Measuring pressure in heart or blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3639—Blood pressure control, pressure transducers specially adapted therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3653—Interfaces between patient blood circulation and extra-corporal blood circuit
- A61M1/3656—Monitoring patency or flow at connection sites; Detecting disconnections
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3331—Pressure; Flow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/52—General characteristics of the apparatus with microprocessors or computers with memories providing a history of measured variating parameters of apparatus or patient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/04—Heartbeat characteristics, e.g. ECG, blood pressure modulation
Definitions
- the present invention relates to a method according to the preamble of claim 1 for determining and / or monitoring a physical condition of a patient and a device according to claim 17 for carrying out the method according to the invention. It further relates to a device according to the preamble of claim 18 and a treatment device according to claim 23.
- the object of the invention is achieved by a method having the features of claim 1.
- the method according to the invention comprises evaluating an amplitude of a pressure signal.
- An amplitude of a pressure signal is understood according to the invention as a single value - and in particular its height - not as a signal.
- Detecting the heart rate for assessing the physical condition of a patient is already known as explained above.
- an "amplitude of a pressure signal” can also advantageously be used to assess the physical condition of the patient under "amplitude of a pressure signal" on the body of a patient or extracorporeal -.
- amplitude of a pressure signal in particular an amplitude of a cardiac pressure signal of the patient or an approximation thereof to understand.
- the fluctuations in the amplitude of the pressure signal and in particular the amplitude of the cardiac pressure signal can be determined by the stroke volume of the heart, cardiac output, ejection, contractility, heart valve defects, vascular status, in particular
- Diabetes patients - or changes thereof may also be due to engineering or other circumstances such as site of puncture, needle size, compliance of a system being used, patient's position changes, patient's movements, recirculation, hydrostatic pressure strokes, TPR (total peripheral resistance or vascular resistance in peripheral blood vessels) or the like conditional.
- the evaluation of the amplitude of the pressure signal and above all the amplitude of the cardiac pressure signal can advantageously be used to assess the above-mentioned and other phenomena or changes in the sense of a "physical condition", as understood in the present case Stroke volume or cardiac output of the heart by means of an evaluation of the amplitude of the pressure signal of great interest.
- an "amplitude of the pressure signal” may denote the determined or measured value of the pressure signal-or its height-in a maximum deflection or in a maximum .
- the maximum deflection may be expressed as the difference between the value of the maximum pressure peak and a baseline.
- the amplitude of the pressure signal may also be determined in other ways.
- the "determination and / or monitoring of at least one physical condition” or a size related to the physical condition of a patient may be used both to assess a pathological condition It may be used to monitor and / or to accompany or monitor a patient's treatment and / or for diagnostic purposes.
- the determination and / or monitoring can take place without comparing the amplitude of the pressure signal or the evaluation results with reference values of further patients.
- the pursuit of an intra-individual development or change in the amplitude of the pressure signal always the same patient over a period of time already lead to a statement about the physical condition.
- a comparison with reference data of third parties is obviously not necessary, but possible and provided in a preferred embodiment.
- Detecting and / or monitoring may be done while the patient is being treated, but it may be too at a later time without the presence of the patient or without the patient still being connected to a device for determining the amplitude of the pressure signal and / or a treatment device. Furthermore, the amplitude of the pressure signal need not be determined in the narrower sense on the patient. The amplitude of the pressure signal may also have been determined extracorporeally on a blood pump, a blood circulation or the like.
- a "size relating to the physical condition of a patient” or a “physical condition” may be any size, in particular physiological, that is suitable as a characteristic quantity for assessing and characterizing the physical condition - or a partial aspect thereof - of a patient.
- cardiovascular parameters such as fistula perfusion in a fistulized or shunted dialysis patient, heart rate, cardiac pressure amplitude, fistula condition, arrhythmia, pacemaker function, and respiratory variables.
- respiratory size may be a respiratory signal such as respiratory rate, a pathological breathing pattern such as paradoxical breathing, and the like.
- the physical condition is not already understood to mean the amplitude of the pressure signal and in particular not the amplitude of the cardiac pressure signal. Only their evaluation, not already their measurement or determination, allows inference to the physical condition in the sense of the present invention.
- a "patient” within the meaning of the present invention may be a member of any species (human or animal), whether ill or healthy.
- the "evaluation of the amplitude of the pressure signal” can, for example, by means of appropriate and possibly different evaluation and / or
- the "evaluation of the amplitude of the pressure signal” both an exact evaluation of the height or the course of the amplitude of the pressure signal - for example by means of various arithmetic operations - as well as an estimation of the height or the course of the amplitude of the pressure signal or a trend thereof from the determined
- the evaluation required in the individual case may differ from patient to patient, and a person skilled in the art may determine on the basis of the given circumstances which type of evaluation seems to be suitable for optimum care of the patient Assignment to certain clinical pictures or symptoms is not necessary and not intended for the execution of the method according to the invention, but the method according to the invention is rather for achieving key figures, parameter values and the like also for the step of the evaluation.
- the amplitude of the pressure signal For the purpose of "evaluating" the amplitude of the pressure signal, it is possible according to the invention to use any information which can be detected or deduced from the amplitude and also information derivable from the measurement or determination conditions become. So already the height of the amplitude can allow a statement. Also, a level of amplitude compared to amplitudes of other patients may allow a statement; Their comparison with such data and the drawing of knowledge from this can therefore also be an evaluation within the meaning of the invention. Furthermore, the course of the amplitude can give information about the physical condition. In this case, the progression can correspond to or be taken from a representation of a plurality of heart amplitude values over time.
- evaluating it is also possible to understand the average amplitude of the pressure and in particular of the cardiac pressure signal, for example during a treatment session of the patient or another time period .. For example, over 10-second intervals during a treatment quasi-stationary values for the amplitudes of the Pressure signal determined, so you can over these values (ie over the course of time away) form the mean or median, and thus receives per treatment - or for a period of time in general - a value over a longer period (weeks / months) away Also by evaluating this value are
- the amplitude of the pressure signal alone can be evaluated.
- additional size may be considered for determining and / or monitoring become.
- the sizes can be measured at the same or different times.
- the sizes may be directly related or independent of each other.
- variable-as well as the amplitude of the pressure signal-can also be determined and / or monitored by not being detected directly as a measured value, but obtained by evaluating, filtering, converting or the like another variable, in particular measured.
- the other size may be an otherwise accessible size.
- the above-mentioned evaluation can be supplemented for example by measuring and evaluating additional variables such as heart rate, average fistula pressure (P art (arterial fistula pressure) + P ve n (venous fistula pressure) / 2) or other parameters, in particular dialysis-specific parameters.
- an "evaluation” does not necessarily have to provide exact values, but it may also be sufficient to determine an approximation to the actual exact values, which may also lead to a progression of the determined values and thus a trend of the same
- Such an approach can be used to further reduce the effort required for the evaluation of the determined quantity, so that both the expenditure on equipment and the amount of computation required for evaluating the amplitude of the pressure signal can be advantageously reduced.
- pressure signal may be understood as a continuous pressure signal, if sufficiently sampled (eg 20 Hz) become. This signal can be subdivided into small time periods of, for example, 10 seconds, in which frequency and amplitude are considered constant (it is then spoken of a stationary signal).
- the pressure signal may be composed of different signals.
- a portion of the pressure signal may be a cardiac pressure signal, that is, a signal caused by the cardiac contraction.
- Another component may be a pump pressure signal, that is to say a pressure signal, which may be continuous, caused by a blood pump.
- the amplitude of the pressure signal or else a cardiac pressure signal
- the amplitude of a stationary or approximately stationary (quasi-stationary) (cardiac) pressure signal section is understood according to the invention, for example over a time window of 10 seconds
- the time window may have a duration of between 1 and 5 minutes.
- the amplitude of the pressure signal evaluated by means of the method according to the invention can be determined during a blood treatment session using a blood treatment device. In particular, it can be determined or measured extracorporeally.
- a "blood treatment device” can be used for blood treatment and / or blood purification and as a Dialysis device or an infusion pump be designed, which is connected, for example by means of shunt, fistula or catheter with the vascular system of the patient.
- a dialysis device may include a device for hemodialysis, hemofiltration or hemodiafiltration. Such devices regularly have an extracorporeal blood pump.
- An "amplitude of a pressure signal" may be measured in the extracorporeal blood circuit with one or more of the pressure sensors provided in a blood treatment device.
- Suitable pressure sensors are well known in the art and include, but are not limited to, piezoelectric, piezoresistive, frequency-analog, capacitive, inductive pressure sensors and / or pressure sensors with Hall elements and combinations thereof.
- Such a pressure sensor may be present in the arterial or venous branch of the tubing system or other sections, in particular to the blood pump of the blood treatment device, be integrated.
- the amplitude of the pressure signal may include further undesired pressure signals, such as spurious signals, which may originate from other devices used in the blood treatment device, and / or measurement noise.
- the measurement noise can be eliminated, for example, via a simple bandpass filter.
- the method comprises a step of correcting the value of the amplitude of the pressure signal by a contribution of
- Blood treatment device for the magnitude of the amplitude of the pressure signal.
- Such a contribution may be, for example, an amplitude of the pressure signal or its height derived from an extracorporeal blood pump used in the treatment of blood.
- the "correction of the amplitude of the pressure signal” can be carried out according to the methods known from EP 0 330 761 A1 and EP 0 957 956 B1, the disclosure of which is incorporated herein by reference in its entirety.
- the method known from the dissertation of one of the inventors of the present invention Ulrich Moissl, entitled “Cardiovascular Monitoring in Hemodialysis Therapy", Technische Vietnamese Darmstadt, Germany, 2005, can be used as well
- the amplitude of the cardiac pressure signal becomes submerged during the patient's extracorporeal blood treatment at exemplary intervals of 10 seconds each
- Correcting the magnitude of the amplitude of the pressure signal may occur simultaneously with the measurement thereof or at a later time. For example, it can be done automatically at certain predetermined times.
- the intervals between times may vary depending on external conditions or measurement results.
- a further preferred embodiment of the method provides for correcting the value of the amplitude of the pressure signal as a function of a signal transmitted by at least one position sensor.
- the position sensor allows a scan of the cardiac pressure signal to a constant angle of rotation of the pump rotor.
- the position sensor may be or cooperate with a Hall sensor which emits a pulse, but also as an optical sensor, e.g. recognizes a black line on the rotor, or in any other, known in the art, be configured.
- a “Hall sensor” is a device for measuring an electrical voltage in a current-carrying conductor, which is located in a stationary
- Hall sensors Magnetic field is located.
- the functioning of Hall sensors is described, for example, in the paper by Josef Janisch, "What You Ever Wanted to Know About Hall Sensors: Small Effect - Great Impact", pages 1 to 5, elektronik industrie 7, 2006.
- the Hall sensor or sensors can be used according to the invention as described in DE 102 30 413 Al, the relevant disclosure of which is hereby fully incorporated by reference.
- Such a contribution may be a magnitude of an amplitude of the pressure signal from the blood pump.
- the pressure signal is effectively undersampled with respect to the relevant cardiac signal components.
- the amplitude of the heart pressure can not be continuously calculated here due to the undersampling, but one obtains sufficiently many values of, for example, over a period of minutes considered as constant course of the pressure signal and in particular of the cardiac pressure signal.
- the amplitude which represents the maximum value of the pressure signal, can be estimated from the determined pressure signal values. If a maximum value of the pressure signal is always determined, this implicitly even results in its amplitude.
- the histogram can also be built up by a time-synchronous sampling.
- the method comprises correcting the magnitude of the amplitude of the
- a “peristaltic blood pump” is a positive displacement pump commonly used in a blood treatment and / or blood purification process
- Promoting blood flow in extracorporeal blood circulation can be designed, for example, as a roller pump.
- Blood pump “means that the amplitude of the pressure signal is corrected by a specific signal of the blood pump, which correlates with a certain rotation angle of the blood pump, that is, the respective amplitudes measured at a certain rotation angle of the blood pump and / or under
- the method comprises evaluating the value of the corrected amplitude of the
- Pressure signal by comparing the amplitude with predetermined reference values.
- predetermined reference values may be from the same patient and / or values obtained by other patients and / or empirical values and / or values from pathologically unremarkable persons.
- a repeated evaluation of the amplitude can also serve to map a course of treatment or to detect a treatment success.
- a further preferred development of the method according to the invention comprises the extracorporeal determination or measuring of the amplitude of the pressure signal. More preferred is the Method according to the invention carried out as an offline method, so that the patient advantageously does not have to be present for the determination or the evaluation. For example, it does not have to remain connected to a treatment device for evaluation.
- the monitored or determined variable is a respiration signal.
- the respiratory signal can be determined in patients with a cardiac catheter by measurements in the right atrium of the patient and, for example, the respiratory rate and / or the depth of breath of one or more breaths.
- a respiratory profile of the patient can be imaged and thus respiratory fluctuations or an uneven one
- the method according to the invention further comprises an evaluation of the amplitude the pressure signal to observe a long-term trend of, in particular cardiovascular, sizes.
- the "monitoring of the long-term trend" may comprise a period of several hours to a few weeks and / or months, and such a period may span a plurality or a multiplicity of dialysis treatments in a dialysis patient.
- a fistula and in particular a new fistula installation can be monitored over several months by evaluating the pressure amplitude signal in order to detect changes in the vascular access before they become critical or in need of treatment.
- evaluating the pressure amplitude signal in order to detect changes in the vascular access before they become critical or in need of treatment.
- Beginning stenoses can be detected and dilated in good time if necessary, for example by using balloon catheters.
- amplitude of the patient's cardiac pressure signal possibly in addition to a change in the heart rate, mean fistula pressure or a change thereof and / or other dialysis-specific variables or their change - in a long-term monitoring.
- the method according to the invention can be used during a blood treatment, in particular hemodialysis, hemofiltration or hemodiafiltration. It may be advantageous to use the measuring and / or evaluation devices of the blood treatment device already provided for the blood treatment for carrying out the method according to the invention.
- the method according to the invention serves to create a classification of a patient with the advantages known for this purpose.
- the accuracy of the statement for an individual patient can be increased by classification.
- the quantity to be determined and / or monitored is a heart rate and / or an arrhythmia and / or the function of a cardiac pacemaker.
- Potassium content is increased or their composition is changed otherwise.
- a Fourier spectrum of the cardiac amplitudes can be formed over a treatment or a treatment excerpt (for example 10 to 30 minutes). This allows rhythmic changes of the Heart signal amplitude are detected. From the perspective of a continuous 20 Hz cardiac pressure signal that would be an amplitude modulation. In analogy to the "Heart Rate Variability" one could, for example, speak of a "Heart Amplitude Variability".
- This procedure could e.g. reflect the influence of hormonal blood pressure regulation of the baroreceptor loop or similar long-term control loop oscillations, but also a short-term beat-to-beat modulation of the
- the present invention is not limited to the sizes exemplified herein. If desired, it is also possible to determine and / or monitor other quantities, not mentioned here, in particular physiological quantities.
- the object of the present invention is further achieved with a device according to claim 17.
- the device according to the invention can in each case be used for carrying out the method according to the invention in each of its
- Embodiments have required and suitable facilities. To avoid repetitions of the function of the individual components, elements and / or advantages, reference is made to the components, elements and / or method steps explained in connection with the method according to the invention. Leave by means of the device according to the invention to achieve the benefits achieved by the method according to the invention undiminished.
- the object according to the invention is also achieved with a device according to claim 18.
- This device according to the invention has at least corresponding devices for evaluating and possibly measuring an amplitude of a pressure signal.
- each device according to the invention can be or have automated devices and / or data processing devices, such as a CPU.
- the amplitude of the pressure signal can be statistically evaluated by means of appropriate facilities. It can like the heart rate by means of appropriate facilities during a dialysis treatment extracted from the measured at the extracorporeal blood circuit amplitude of the pressure signal and possibly recorded.
- the device according to the invention further comprises at least one means for correcting the value of the amplitude of the pressure signal by a contribution of one
- Blood treatment device for the magnitude of the amplitude of the pressure signal in response to a signal or pulse at least one position sensor or Hall sensor and / or depending on the angle of rotation of another suitable technical size of a blood pump of the blood treatment device.
- Such a contribution may be an amplitude of the pressure signal of a blood pump.
- the correction of the amplitude of the pressure signal is preferably carried out automatically.
- Pressure signal may be predetermined by a specific signal at least one Hall sensor and / or a certain angle of rotation of a blood pump of the blood treatment device.
- the pump signal can already be implicitly corrected.
- the pressure contribution of the pump is always the same in the optimal case and is z.
- the fistula pressure can be calculated from this: If the geometry of the pump, needle and tube is identical or comparable, and the blood viscosity / hematocrit is given, a pure pump pressure curve can be recorded in the laboratory.
- the difference between their course and a course of the measured values or the pressure signal is the fistula pressure, provided that all other conditions correspond to the laboratory environment; otherwise, an approximation of the fistula pressure or its course can be obtained by the above-mentioned procedure.
- the device also has a device for holding reference values.
- This device may serve to store the reference values and may be a storage device which is common in the art and suitable for this purpose, such as a ROM, a RAM, a floppy disk, a memory card, a USB stick and the like.
- the device according to the invention may further comprise further means for filtering interfering signals and / or for
- the filtering can be as in the o. G. Dissertation described. Its content is included here by reference.
- a blood treatment device comprises at least one device according to the invention as described above.
- a blood treatment device may be configured as a dialysis device, as described above in connection with a blood treatment.
- the method according to the invention and the device according to the invention it is advantageously possible, at least a, in particular cardiovascular, size to determine or monitor the physical condition of a patient.
- This can be done according to the invention without special effort and also non-invasive. Its execution is also possible without significant additional equipment expense, especially during a blood treatment.
- the method according to the invention advantageously makes it possible in particular to detect a change in a vascular access (eg fistula or shunt). This applies in particular to a long-term monitoring of the amplitude of the pressure signal.
- special training and / or training of the hospital staff and / or the staff in medical practices is advantageously not required.
- the inventive method is therefore characterized by its ease of execution and comparatively easy readability. This is especially true when measuring the amplitude of the pressure signal at a certain predetermined time of a Hall sensor signal and / or rotationally synchronous with the blood pump provided in the blood treatment device and correcting the detected amplitude of the pressure signal by a known contribution of the blood treatment device to the signal, for example by the contribution of the blood pump , If the amplitude of the pressure signal of the blood pump at a certain rotation angle is known, the correction can be advantageously further simplified, since in each case a substantially equal amount for the value of the contribution of the blood pump to the height of the amplitude assumed and the determined amplitude of the pressure signal in each case known value can be corrected to obtain the desired amplitude of the patient's heart signal or an approximate value. This can be particularly advantageous if the blood pump is not sufficient evenly rotated.
- the ability to detect calcifications within a fistula or in the patient's vasculature is another advantageous application of the present invention.
- the amplitude of the cardiac pressure signal can be determined if the contribution of the pump is always the same (which is guaranteed by the Hall sensor synchronous sensing at always the same rotor position) or at least approximately the same.
- Evaluating the amplitude of the pressure signal, the amplitude of the cardiac pressure signal of a patient, or an approximation thereof, may be advantageously used for locating stenoses and / or assessing the condition of a fistula and for timely prevention of critical conditions.
- By comparing the desired characteristic quantities with reference values and / or observing a trend of the magnitudes the development of a pathological condition can be prevented and / or the deterioration to a critical condition can be prevented.
- the execution of the invention The method does not inconvenience a patient, especially if the method - which is also usable online - is used offline, which is an advantage of the offline implementation.
- a further advantage of the method according to the invention is that the patient does not have to be present at the time of the evaluation.
- the combination of the method according to the invention with a blood treatment such as hemodialysis, hemofiltration or hemodiafiltration, as well as the combination of the device according to the invention with a suitable for this purpose blood treatment device requires little expenditure on equipment and can thus save both time and costs as well as further inconvenience to the patient advantageous to avoid.
- Pulse amplitude If, for example, the pulse amplitude decreases during treatment, this may be due to a decrease in stroke volume or to a decrease in fistula pressure. It may accordingly be possible to take into account mathematically the effect of the stroke volume on the recorded heart rate and thus to conclude on a relative change in the fistula pressure. Furthermore, it may be possible to conclude on the blood supply of the fistula via the determination of the amplitude of the pressure signal at different rotational speeds of the blood pump and thus, if appropriate, to estimate the fistula flow.
- the method according to the invention is also described above in connection with a blood treatment device, the present invention is not limited to use in a patient in which a blood treatment and / or blood purification is performed by means of a corresponding device.
- Fig. 1 shows schematically the principle of a cardiac signal extraction
- FIG. 2 shows graphs of a heart rate (above) and an amplitude of a cardiac pressure signal (below) above FIG. 2
- FIG. 3 shows value ranges of amplitudes of the
- Fig. 4 shows graphs of a heart rate (above) and an amplitude of a heart pressure signal (below) versus time;
- Fig. 5 is a graph showing a superposition of influences of respiration and the amplitude of the cardiac pressure signal over time
- Fig. 6 is a graph showing Cheyne-Stokes respiration
- Fig. 7 shows further graphs of a heart rate (above) and an amplitude of a cardiac pressure signal (below) versus time;
- Fig. 8 shows schematically the extraction of a
- FIG. 9 schematically shows the deviation of a pump frequency from a nominal frequency (FIG. 9a) and the difference between a time-synchronous (FIG. 9b) and an angle-synchronous (FIG. 9c) sampling of the pump signal;
- FIG. 10 shows a graph of an amplitude of a cardiac pressure signal versus a corrected fistula pressure.
- Fig. 1 illustrates, schematically simplified, the principle of cardiac signal extraction.
- a fistula (not shown) was applied for the purpose of blood treatment.
- the fistula is connected to a blood treatment device 5, which has an arterial limb 7 and a venous limb 9.
- the blood treatment device 5 has a dialyzer 15, and on its arterial side a pressure sensor 11, a blood pump 13, on its venous side a pressure sensor 17 and a drip chamber 19.
- the pressure signal 21 detected by the pressure sensor 11 comprises the cardiac pressure signal 23 of the patient 1, a contribution 25 from the blood pump 13 and a measurement noise 27.
- the amplitude of the cardiac pressure signal 23 can be determined according to the present invention from the detected pressure signal 21. An evaluation of the amplitude of the determined cardiac pressure signal 23 is as described above also subject of the present invention.
- Fig. 2 shows graphs of a heart rate 29 (above, given in [bpm], ie beats per minute) and an amplitude of a cardiac pressure signal 23 (below) over the duration of a blood treatment.
- the heart rate was validated by the inventors using a standard ECG device.
- the base frequency 25 of the blood pump of the blood treatment device used is designated 5008 of
- the course of the heart rate 29 has in Fig. 2 on some jumps.
- the heart rate 29 is expected to increase at time 31 of the patient's waking up, at time 33 of breakfast, at time 35 at the midpoint of treatment, or at a time 37 visit.
- the cardiac pressure signal 23 is also subject to significant trends. Its amplitude varies between approximately 4 and 1 mmHg.
- FIG. 3 shows values for the amplitudes of a cardiac pressure signal in mmHg over a time between February (02/08) and September (09/08) of the year 2008.
- the bars 38 respectively represent the median 39 and the tenth and ninetieth percentile of the amplitudes of the Heart pressure signal of a complete treatment dar.
- a fistula new plant at a time 40 as a graft previously a central venous catheter was used.
- the mean amplitude of the cardiac pressure signal then continued to increase over weeks, suggesting a developing fistula outflow stenosis.
- Outflow canals occur regularly in Goretex grafts.
- the period observed here represents approximately the maturation time for the graft.
- a range can be defined in the amplitude of the cardiac pressure signal should be long term.
- a drainage stenosis with an amplitude of the cardiac pressure signal of> 20 mmHg can already significantly restrict the fistula flow.
- Such an area may be universal or newly determined for each patient.
- the long-term monitoring of the amplitude of the cardiac pressure signal can be used to detect changes in the vascular access.
- FIG. 4 shows graphs of a heart rate 29 (above) and an amplitude of a cardiac pressure signal 23 (below) versus time.
- the jump to time 41 occurring in both graphs after approximately 130 minutes reflects a transition to intermittent atrial fibrillation. Such a process leads to a high irregular pulse, as can be seen in Fig. 4 above.
- FIG. 5 graphically illustrates a superposition 43 of influences of respiration and cardiac pressure signal over time.
- the overlay 43 is composed of small peaks of the heartbeat and large fluctuations of the respiration. Breathing is particularly in catheterized patients when measured in the right atrium representable. The intrathoracic pressure of respiration is detectable as shown in FIG.
- Fig. 6 shows Cheyne-Stokes respiration. This takes five to six consecutive breaths followed by a breathing pause. In the breathing space the cardiac pulsation is clearly recognizable on the basis of the characteristic amplitude of the cardiac pressure signal 23.
- FIG. 7 shows in a further graph a heart rate (top) and the amplitude of a heart pressure signal (bottom) currently.
- the corresponding data were obtained from a pacemaker patient.
- the pacemaker only "intervenes” occasionally, resulting in the two different heart rates shown.
- FIG. 8 shows schematically the extraction of a cardiac pressure signal 23 from a measurement signal 45, which in addition to the cardiac pressure signal also has a pump signal (top), and a corresponding histogram (below). The extraction of the cardiac pressure signal 23 takes place by detecting
- Hall sensor signals of a blood pump such as a blood pump of a dialysis machine of the machine generation with the name 5008 from Fresenius Medical Care.
- the circles 47 reproduce the Hall sensor synchronous scanning.
- Circles 49 indicate the cardiac pressure signal at the time of the Hall sensor pulses. Scanning is done with each Hall sensor pulse.
- the histogram represents the values of circles 49. Standard deviations can be understood as a measure of the strength of the pulsation.
- the mean value in the histogram can give or make a statement about the fistula pressure.
- the cardiac pressure amplitude for example, the mean +/- one standard deviation serve. It is also possible to use a percentile (10th, 90th, etc.), a percentile range, or combinations thereof.
- FIG. 9 schematically shows the difference between a time-synchronous (FIG. 9b) and an angle-synchronous (FIG. 9c) sampling of the pump signal.
- the arterial pressure signal can also be sampled angle synchronously with a pump rotor. This can improve the extraction of the cardiac pressure signal, especially if the blood pump does not rotate completely uniformly, i. h if the Pump frequency 51 deviates from a nominal frequency 53 as shown in Fig. 9a.
- the unit [Hz] stands for the pump frequency.
- FIG. 10 shows a graph of a cardiac pressure signal 23 over a hydrostatically corrected fistula pressure P Forr (at the arterial needle within the fistula) with values from more than 50 dialysis treatments.
- P Forr at the arterial needle within the fistula
- this is due to the drop in stroke volume: as the blood supply during treatment decreases, so does the stroke volume, which compensatively leads to an increased heart rate.
- this can be explained by a decrease in fistula pressure.
- a relative change in fistula pressure may be inferred when the impact volume effect is corrected, for example, over the heart rate.
- the relationship between fistula pressure and amplitude may also be due to the elasticity of the fistula.
- a bulging fistula can not stretch further and transmits heart pulses with less damping or almost no damping.
- An empty, sagging fistula dampens the pulsation more. Further, by determining the amplitude at different rotational speeds of the blood pump, it is possible to deduce the blood supply of the fistula and thus to make an estimate of the fistula flow.
Landscapes
- Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- External Artificial Organs (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102008061122A DE102008061122A1 (de) | 2008-12-09 | 2008-12-09 | Verfahren und Vorrichtung zum Ermitteln und/oder Überwachen eines körperlichen Zustandes, insbesondere einer kardiovaskulären Größe, eines Patienten basierend auf einer Amplitude eines Drucksignals |
| PCT/EP2009/008765 WO2010066405A2 (de) | 2008-12-09 | 2009-12-08 | Verfahren und vorrichtung zum ermitteln und/oder überwachen eines körperlichen zustandes, insbesondere einer kardiovaskulären grösse, eines patientes basierend auf einer amplitude eines drucksignals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP2384138A2 true EP2384138A2 (de) | 2011-11-09 |
| EP2384138B1 EP2384138B1 (de) | 2018-09-26 |
Family
ID=41786317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP09765044.4A Active EP2384138B1 (de) | 2008-12-09 | 2009-12-08 | Vorrichtung zum ermitteln und/oder überwachen einer fisteldurchgängigkeit basierend auf einer amplitude des herzdrucksignals während einer blutbehandlung |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20110301472A1 (de) |
| EP (1) | EP2384138B1 (de) |
| DE (1) | DE102008061122A1 (de) |
| ES (1) | ES2702449T3 (de) |
| WO (1) | WO2010066405A2 (de) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020244965A1 (de) * | 2019-06-01 | 2020-12-10 | Man Truck & Bus Se | Verfahren und vorrichtung zur bestimmung einer amplitude einer pumpeninduzierten fluiddruckschwankung eines fluids |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8152751B2 (en) | 2007-02-09 | 2012-04-10 | Baxter International Inc. | Acoustic access disconnection systems and methods |
| CN102076369B (zh) | 2008-06-26 | 2014-04-23 | 甘布罗伦迪亚股份公司 | 用于监控流体连接的完整性的方法和装置 |
| US9677555B2 (en) | 2011-12-21 | 2017-06-13 | Deka Products Limited Partnership | System, method, and apparatus for infusing fluid |
| US9456755B2 (en) | 2011-04-29 | 2016-10-04 | Medtronic, Inc. | Method and device to monitor patients with kidney disease |
| US9750862B2 (en) | 2011-04-29 | 2017-09-05 | Medtronic, Inc. | Adaptive system for blood fluid removal |
| US9848778B2 (en) | 2011-04-29 | 2017-12-26 | Medtronic, Inc. | Method and device to monitor patients with kidney disease |
| AU2012278038B2 (en) | 2011-06-30 | 2014-11-13 | Gambro Lundia Ab | Filtering of a time-dependent pressure signal |
| US10563681B2 (en) | 2011-12-21 | 2020-02-18 | Deka Products Limited Partnership | System, method, and apparatus for clamping |
| US11295846B2 (en) | 2011-12-21 | 2022-04-05 | Deka Products Limited Partnership | System, method, and apparatus for infusing fluid |
| US9675756B2 (en) | 2011-12-21 | 2017-06-13 | Deka Products Limited Partnership | Apparatus for infusing fluid |
| JP6199312B2 (ja) * | 2012-01-27 | 2017-09-20 | レスメド・リミテッドResMed Limited | チェーンストークス呼吸パターンの判別 |
| AU2013201556B2 (en) | 2012-07-13 | 2014-06-05 | Gambro Lundia Ab | Filtering of pressure signals for suppression of periodic pulses |
| KR102262451B1 (ko) | 2013-03-20 | 2021-06-07 | 감브로 룬디아 아베 | 체외 혈액 처리 장치에 연결된 환자의 심정지의 모니터링 |
| DE102013007044A1 (de) | 2013-04-24 | 2014-10-30 | Fresenius Medical Care Deutschland Gmbh | Steuereinheit und Verfahren zur Bestimmung eines Drucks in einem Blutgefäß, insbesondere in einer arteriovenösen Fistel |
| EP2823834B1 (de) * | 2013-07-10 | 2016-06-22 | Gambro Lundia | Vorrichtung zur extrakorporalen Blutbehandlung |
| EP3102107A4 (de) | 2013-11-04 | 2018-02-07 | Medtronic, Inc. | Verfahren und vorrichtung zur verwaltung von fluidvolumina im körper |
| ES3040293T3 (en) | 2013-11-27 | 2025-10-29 | Mozarc Medical Us Llc | Precision dialysis monitoring and synchonization system |
| DE102014102732A1 (de) * | 2014-02-28 | 2015-09-03 | B. Braun Avitum Ag | System und Verfahren zur Erkennung einer venösen Nadeldiskonnektion |
| DE102014102731A1 (de) | 2014-02-28 | 2015-09-03 | B. Braun Avitum Ag | Vorrichtung und Verfahren zur Erkennung einer venösen Nadeldiskonnektion |
| CN106794302B (zh) | 2014-09-18 | 2020-03-20 | 德卡产品有限公司 | 通过将管适当加热来穿过管输注流体的装置和方法 |
| WO2017078965A1 (en) | 2015-11-06 | 2017-05-11 | Medtronic, Inc | Dialysis prescription optimization for decreased arrhythmias |
| US10994064B2 (en) | 2016-08-10 | 2021-05-04 | Medtronic, Inc. | Peritoneal dialysate flow path sensing |
| US10874790B2 (en) | 2016-08-10 | 2020-12-29 | Medtronic, Inc. | Peritoneal dialysis intracycle osmotic agent adjustment |
| US12329892B2 (en) | 2016-04-04 | 2025-06-17 | Mozarc Medical Us Llc | Dextrose concentration sensor for a peritoneal dialysis system |
| US10952666B2 (en) * | 2016-06-24 | 2021-03-23 | Fresenius Medical Care Holdings, Inc. | System and method for managing nocturnal treatment |
| US11013843B2 (en) | 2016-09-09 | 2021-05-25 | Medtronic, Inc. | Peritoneal dialysis fluid testing system |
| US10607590B2 (en) * | 2017-09-05 | 2020-03-31 | Fresenius Medical Care Holdings, Inc. | Masking noises from medical devices, including dialysis machines |
| WO2020037216A2 (en) | 2018-08-16 | 2020-02-20 | Deka Products Limited Partnership | Medical pump |
| US11806457B2 (en) | 2018-11-16 | 2023-11-07 | Mozarc Medical Us Llc | Peritoneal dialysis adequacy meaurements |
| US11806456B2 (en) | 2018-12-10 | 2023-11-07 | Mozarc Medical Us Llc | Precision peritoneal dialysis therapy based on dialysis adequacy measurements |
| US12433976B2 (en) | 2019-01-08 | 2025-10-07 | Mozarc Medical Us Llc | Bicarbonate sensor for dialysis |
| US11923078B2 (en) | 2019-11-01 | 2024-03-05 | Terumo Cardiovascular Systems Corporation | Semi-autonomous medical systems and methods |
| US12154673B2 (en) | 2021-08-02 | 2024-11-26 | Mozarc Medical Us Llc | Artificial intelligence assisted home therapy settings for dialysis |
| US11850344B2 (en) | 2021-08-11 | 2023-12-26 | Mozarc Medical Us Llc | Gas bubble sensor |
| US11965763B2 (en) | 2021-11-12 | 2024-04-23 | Mozarc Medical Us Llc | Determining fluid flow across rotary pump |
| US11944733B2 (en) | 2021-11-18 | 2024-04-02 | Mozarc Medical Us Llc | Sodium and bicarbonate control |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4370983A (en) * | 1971-01-20 | 1983-02-01 | Lichtenstein Eric Stefan | Computer-control medical care system |
| US4710164A (en) * | 1984-05-01 | 1987-12-01 | Henry Ford Hospital | Automated hemodialysis control based upon patient blood pressure and heart rate |
| DE3806248A1 (de) | 1988-02-27 | 1989-09-07 | Fresenius Ag | Mess-/anzeigeverfahren bei fluessigkeitssystemen medizinischer geraete und vorrichtung zur durchfuehrung des verfahrens |
| IT1219379B (it) * | 1988-06-15 | 1990-05-11 | Hospal Dasco Spa | Metodo e apparecchiatura per la previsione degli effetti collaterali che si manifestano in un paziente durante un trattamento di dialisi |
| SE508374C2 (sv) | 1995-09-12 | 1998-09-28 | Gambro Med Tech Ab | Förfarande och anordning för detektering av tillståndet hos en blodkärlsaccess |
| WO1997011637A1 (en) * | 1995-09-28 | 1997-04-03 | Data Sciences International, Inc. | Respiration monitoring system based on sensed blood pressure |
| US6779468B1 (en) * | 1997-08-07 | 2004-08-24 | Ajay Gupta | Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients |
| DE19848235C1 (de) * | 1998-10-20 | 2000-03-16 | Fresenius Medical Care De Gmbh | Verfahren zur Überwachung eines Gefäßzuganges und Vorrichtung zur extrakorporalen Blutbehandlung mit einer Einrichtung zur Überwachung des Gefäßzuganges |
| DE19901078C1 (de) * | 1999-01-14 | 2000-02-17 | Polaschegg Hans Dietrich | Verfahren und Vorrichtung zur Erkennung von Stenosen bei der extrakorporalen Blutbehandlung |
| US6691047B1 (en) * | 2000-03-16 | 2004-02-10 | Aksys, Ltd. | Calibration of pumps, such as blood pumps of dialysis machine |
| SE522400C2 (sv) * | 2000-04-19 | 2004-02-03 | Gambro Lundia Ab | Förfarande och en anordning för övervakning av strömningshastigheten för en infusionslösning |
| ES2304385T3 (es) * | 2000-04-25 | 2008-10-16 | Rodenstock Gmbh | Cristal de gafas progresivo. |
| DE10033192B4 (de) * | 2000-07-07 | 2007-10-18 | Fresenius Medical Care Deutschland Gmbh | Verfahren zur Detektion arterieller Einlaufprobleme während einer extrakorporalen Blutbehandlung und extrakorporale Blutbehandlungsvorrichtung |
| AU2001288989A1 (en) * | 2000-09-08 | 2002-03-22 | Wireless Medical, Inc. | Cardiopulmonary monitoring |
| US7527597B2 (en) * | 2001-01-16 | 2009-05-05 | Biomedical Acoustic Research Corporation | Acoustic detection of vascular conditions |
| DE10115991C1 (de) | 2001-03-30 | 2002-04-18 | Fresenius Medical Care De Gmbh | Verfahren und Vorrichtung zum Erkennen von Stenosen in einem Schlauchleitungssystem |
| AU2002322730A1 (en) * | 2001-07-30 | 2003-02-17 | Henry Ford Health System | Access pressure ratio device and testing method |
| DE10159620C1 (de) * | 2001-12-05 | 2003-08-14 | Fresenius Medical Care De Gmbh | Verfahren und Einrichtung zur Überwachung der Zufuhr von Substitutionsflüssigkeit während einer extrakorporalen Blutbehandlung |
| JP2005520091A (ja) * | 2002-02-25 | 2005-07-07 | ヴァネック、ジリ | ペリスタルティックポンプ |
| SG118192A1 (en) * | 2002-07-03 | 2006-01-27 | Univ Singapore | Reducing chromatic aberration in images formed by emission electrons |
| DE10230413B4 (de) | 2002-07-06 | 2004-07-22 | Fresenius Medical Care Deutschland Gmbh | Vorrichtung zur Bestimmung des Blutvolumens während einer extrakorporalen Blutbehandlung |
| US7284956B2 (en) * | 2002-09-10 | 2007-10-23 | Miwatec Co., Ltd. | Methods and apparatus for controlling a continuous flow rotary blood pump |
| AU2003299606A1 (en) * | 2002-12-13 | 2004-07-09 | Bruce W. Smith | Method for aberration detection and measurement |
| WO2005004950A1 (ja) | 2003-07-10 | 2005-01-20 | Nikkiso Co., Ltd. | 脈拍数測定方法、血圧測定方法、及び血管アクセス監視方法、並びにそれらを用いた医療装置 |
| AU2005285526B2 (en) * | 2004-09-13 | 2011-01-20 | Gambro Lundia Ab | Detection of drastic blood pressure changes |
| JP4094600B2 (ja) * | 2004-10-06 | 2008-06-04 | 日機装株式会社 | 血液浄化装置 |
| DE102005023430A1 (de) * | 2005-03-15 | 2006-09-21 | Fresenius Medical Care Deutschland Gmbh | Verfahren und Vorrichtung zur Bestimmung der effektiven Förderrate oder Einstellung der Drehzahl einer peristaltischen Pumpe |
| US20070191717A1 (en) * | 2006-02-13 | 2007-08-16 | Drexel University | Catheter based implanted wireless pressure sensor |
| ATE486046T1 (de) * | 2006-02-17 | 2010-11-15 | Actides Gmbh | Verfahren zur herstellung eines desinfektionsmittels durch elektrochemische aktivierung (eca) von wasser |
| WO2007134394A1 (en) * | 2006-05-22 | 2007-11-29 | Uscom Limited | Cardiac measurement system and method |
| FR2911417B1 (fr) * | 2007-01-17 | 2009-02-27 | Gambro Lundia Ab | Suivi de l'acces vasculaire d'un patient soumis a des seances successives de traitement extracorporel de sang |
| US8562908B2 (en) * | 2007-06-29 | 2013-10-22 | Baxter International Inc. | Devices, systems, and methods for cleaning, disinfecting, rinsing, and priming blood separation devices and associated fluid lines |
| US9370324B2 (en) * | 2008-11-05 | 2016-06-21 | Fresenius Medical Care Holdings, Inc. | Hemodialysis patient data acquisition, management and analysis system |
-
2008
- 2008-12-09 DE DE102008061122A patent/DE102008061122A1/de not_active Ceased
-
2009
- 2009-12-08 US US13/133,048 patent/US20110301472A1/en not_active Abandoned
- 2009-12-08 ES ES09765044T patent/ES2702449T3/es active Active
- 2009-12-08 EP EP09765044.4A patent/EP2384138B1/de active Active
- 2009-12-08 WO PCT/EP2009/008765 patent/WO2010066405A2/de not_active Ceased
Non-Patent Citations (1)
| Title |
|---|
| See references of WO2010066405A3 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020244965A1 (de) * | 2019-06-01 | 2020-12-10 | Man Truck & Bus Se | Verfahren und vorrichtung zur bestimmung einer amplitude einer pumpeninduzierten fluiddruckschwankung eines fluids |
| US12259291B2 (en) | 2019-06-01 | 2025-03-25 | MAN Truck &Bus SE | Method and device for determining an amplitude of a pump-induced fluid pressure fluctuation of a fluid |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2384138B1 (de) | 2018-09-26 |
| DE102008061122A1 (de) | 2010-06-17 |
| US20110301472A1 (en) | 2011-12-08 |
| WO2010066405A2 (de) | 2010-06-17 |
| WO2010066405A3 (de) | 2010-08-19 |
| ES2702449T3 (es) | 2019-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2384138B1 (de) | Vorrichtung zum ermitteln und/oder überwachen einer fisteldurchgängigkeit basierend auf einer amplitude des herzdrucksignals während einer blutbehandlung | |
| EP3801674B1 (de) | Implantierbares, ventrikuläres unterstützungssystem | |
| DE102012007081B4 (de) | Verfahren sowie Mess- und Recheneinheit zur langfristigen Überwachung der arteriellen Gefäßsteifigkeit und Gefäßkalzifikation eines Patienten | |
| EP3416701B1 (de) | Gerät zur extrakorporalen blutbehandlung mit einer auswerte- und steuereinheit | |
| EP1991116B1 (de) | Dialysegerät mit messeinrichtungen zur erfassung des blutdrucks sowie verfahren zur bestimmung des blutdrucks sowie ein speichermedium zur verwendung in einem dialysegerät | |
| DE112012003687T5 (de) | Medizinprodukt mit einem Funktionselement zum invasiven Einsatz im Körper eines Patienten | |
| EP3302231A1 (de) | Verfahren sowie vorrichtung zur ermittlung des verlaufs des blutdrucks | |
| EP4048336B1 (de) | Dialysesystem mit kontinuierlicher glukose-überwachung | |
| DE102013012469A1 (de) | Verfahren zur Messung des Verlaufs von Druckpulswellen bei einer extrakorporalen Blutbehandlung und Vorrichtung zur Durchführung des Verfahrens | |
| EP3145394B1 (de) | Verfahren und vorrichtung zur bestimmung des zentralen systolischen blutdrucks | |
| DE102010061580A1 (de) | Verwendung des Frequenzspektrums eines Artefaktes in der Oszillometrie | |
| WO2011026899A1 (de) | Vorrichtung zur nicht-invasiven bestimmung des arteriellen blutdrucks | |
| EP2658585A2 (de) | Computerbasiertes dialoggerät zur medizinischen überwachung des dialysevorgangs | |
| EP3888549A1 (de) | Bestimmung der atmung mit hilfe eines beschleunigungssensors | |
| WO2022029146A1 (de) | Steuerung für eine extrakorporale kreislaufunterstützung | |
| EP3917386B1 (de) | Verfahren zum bestimmen eines blutdruckwerts eines patienten, blutdruckmessgerät und dialysesystem | |
| WO2018141323A1 (de) | Anordnung mit einer blutpumpe, einer steuereinheit und einem gerät zur übermittlung der messwerte | |
| EP4085825B1 (de) | Blutdruckmessverfahren mit oberarmmanschette | |
| EP3621513A1 (de) | EINRICHTUNG ZUR BESTIMMUNG EINER KENNGRÖßE ZUR DIAGNOSE DES HYDROZEPHALUS UND ANDERER STÖRUNGEN DES HIRNDRUCKS | |
| AT518396B1 (de) | Verfahren und Vorrichtung zum Verarbeiten von Impedanzkardiogrammen zur Beurteilung des Vorliegens einer pulmonalen Hypertonie eines Patienten und Impedanzkardiograph mit einer solchen Vorrichtung | |
| DE102022003277A1 (de) | Steuerung für eine extrakorporale Kreislaufunterstützung bei Herzstimulation | |
| DE102020117132A1 (de) | Medizingerät zum Bestimmen eines Herzzeitvolumen-abhängigen Parameters |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20110624 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
| DAX | Request for extension of the european patent (deleted) | ||
| 17Q | First examination report despatched |
Effective date: 20140709 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| INTG | Intention to grant announced |
Effective date: 20171108 |
|
| GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| INTC | Intention to grant announced (deleted) | ||
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: MOISSL, ULRICH Inventor name: GROEBER, TOBIAS Inventor name: WABEL, PETER |
|
| INTG | Intention to grant announced |
Effective date: 20180420 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1045050 Country of ref document: AT Kind code of ref document: T Effective date: 20181015 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: LANGUAGE OF EP DOCUMENT: GERMAN |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 502009015320 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: P&TS SA, CH |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
| REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181226 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180926 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180926 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181227 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181226 |
|
| REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180926 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180926 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2702449 Country of ref document: ES Kind code of ref document: T3 Effective date: 20190301 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180926 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180926 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180926 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190126 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180926 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180926 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180926 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190126 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 502009015320 Country of ref document: DE |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180926 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180926 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181208 |
|
| 26N | No opposition filed |
Effective date: 20190627 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
| REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20181231 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180926 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181208 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181231 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180926 |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 1045050 Country of ref document: AT Kind code of ref document: T Effective date: 20181208 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180926 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181208 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180926 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180926 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20091208 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20201125 Year of fee payment: 12 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20201119 Year of fee payment: 12 Ref country code: SE Payment date: 20201124 Year of fee payment: 12 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20210107 Year of fee payment: 12 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: MM Effective date: 20220101 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220101 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211209 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211231 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211231 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20230303 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211209 |
|
| P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230602 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20241121 Year of fee payment: 16 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20241122 Year of fee payment: 16 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20241121 Year of fee payment: 16 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20241121 Year of fee payment: 16 |